Anna de Daniel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anna de Daniel has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Carlos Fernández de Larrea
Hospital Clínic de Barcelona, Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
19 shared publications - Joan Bladé
Hospital Clinic de Barcelona 9 Amyloidosis and Myeloma Unit, Department of Hematology IDIBAPS, Barcelona, Spain
18 shared publications - Aina Oliver-Caldés
Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona Barcelona Spain
17 shared publications - David F. Moreno
Amyloidosis and Myeloma Unit, Department of Hematology Hospital Clínic de Barcelona, University of Barcelona Barcelona Spain
16 shared publications - Natalia Tovar
Hospital Clínic, University of Barcelona 14 Barcelona
16 shared publications - Anthony Matthew Battram
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
15 shared publications
Latest Publications
- Open Access
- 25 July 2026
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 61 (10) , 1396-1404
Autologous stem cell transplantation in POEMS syndrome: Multicenter real-world treatment patterns and outcomes
POEMS syndrome is a rare multisystem plasma cell disorder for which evidence guiding management is largely derived from single-center retrospective series. We conducted a retrospective multicenter study including all consecutive patients diagnosed between January 1995 and June 2024 across nine referral hospitals in Catalonia, Spain, within the GEMMAC collaborative network. Clinical characteristics, treatment strategies, transplant outcomes, and long-term survival were analyzed. Forty patients were included, with a median age of 65 years; 25 underwent autologous stem cell transplantation (ASCT). Hematologic response to first-line therapy was achieved in 77.5% of patients. After a median follow-up of 94.2 months, median progression-free survival was 102.6 months and median overall survival was 146.9 months, with 5-year rates of 69.0% and 87.6%, respectively. ASCT was associated with deep and durable hematologic and clinical responses. Baseline ECOG performance status and depth of hematologic response correlated with outcomes. VEGF levels declined markedly after treatment, particularly following ASCT. Transplant-related toxicity was manageable, although late complications were observed. These findings support ASCT as a central therapeutic strategy in eligible patients and underscore the need for long-term follow-up.
- 25 July 2026
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 61 (10) , 1396-1404
Open AccessAutologous stem cell transplantation in POEMS syndrome: Multicenter real-world treatment patterns and outcomes
POEMS syndrome is a rare multisystem plasma cell disorder for which evidence guiding management is largely derived from single-center retrospective series. We conducted a retrospective multicenter study including all consecutive patients diagnosed between January 1995 and June 2024 across nine referral hospitals in Catalonia, Spain, within the GEMMAC collaborative network. Clinical characteristics, treatment strategies, transplant outcomes, and long-term survival were analyzed. Forty patients were included, with a median age of 65 years; 25 underwent autologous stem cell transplantation (ASCT). Hematologic response to first-line therapy was achieved in 77.5% of patients. After a median follow-up of 94.2 months, median progression-free survival was 102.6 months and median overall survival was 146.9 months, with 5-year rates of 69.0% and 87.6%, respectively. ASCT was associated with deep and durable hematologic and clinical responses. Baseline ECOG performance status and depth of hematologic response correlated with outcomes. VEGF levels declined markedly after treatment, particularly following ASCT. Transplant-related toxicity was manageable, although late complications were observed. These findings support ASCT as a central therapeutic strategy in eligible patients and underscore the need for long-term follow-up.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Tables 1-2 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited
ScFv Sequences and antibody panels
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables 1-2 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited
ScFv Sequences and antibody panels
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited
BCMA and CD229 antigen expression on different target cell lines used in different experiments.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited
BCMA and CD229 antigen expression on different target cell lines used in different experiments.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 12 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited
Percentage of PBMCs marked with FAR-RED Cell Trace dead after 24h of co-incubation with respective CAR T cells on a 1:1 ratio, normalized against dead cells from untransduced
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 12 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited
Percentage of PBMCs marked with FAR-RED Cell Trace dead after 24h of co-incubation with respective CAR T cells on a 1:1 ratio, normalized against dead cells from untransduced
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited
CAR T-cell proliferation when co-cultured for 72 hours with K562 cell lines with different expression of CD229 antigen
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited
CAR T-cell proliferation when co-cultured for 72 hours with K562 cell lines with different expression of CD229 antigen
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited
Supplementary Table 3 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited
Supplementary Table 3 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 11 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited
Measurement of the strength of interaction between monospecific and bispecific CAR T cells and MM.1S and MM.1S BCMA KO cells.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 11 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited
Measurement of the strength of interaction between monospecific and bispecific CAR T cells and MM.1S and MM.1S BCMA KO cells.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited
Clones of the K562 tumor cell line with different CD229 expression gradient
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited
Clones of the K562 tumor cell line with different CD229 expression gradient
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited
Specific cytolytic activity of CAR T cells co-culture during 24h with K562 cell lines with different expression of CD229 antigen
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited
Specific cytolytic activity of CAR T cells co-culture during 24h with K562 cell lines with different expression of CD229 antigen
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 10 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited
Generation of a cell line with low BCMA expression (MM.1S BCMA dim) from MM1S BCMA KO cells with an incomplete KO
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 10 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited
Generation of a cell line with low BCMA expression (MM.1S BCMA dim) from MM1S BCMA KO cells with an incomplete KO